Project Term: October 6, 2017 - TBD
In October 2017, NexImmune benefitted from an initial TAP investment and now in 2021 received a second investment as part of the company’s initial public offering to support "A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes in AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT." The antigen-specific T-cell immunotherapy from NexImmune is designed to target multiple tumor antigens associated with AML (NEXI-001). Moreover, in AML patients, CAR-T therapies have yet to demonstrate significant antitumor activity and immunocheckpoint inhibitors have shown only marginal efficacy when given as a monotherapy in blood cancers outside of Hodgkin lymphoma. The initial goal of these early clinical trials is to demonstrate safety, T-cell persistence, and determine preliminary patient benefit.
For additional information, please visit https://lls.org/therapy-acceleration-program-portfolio